Sanofi-backed Welsh biotech secures $140M for neuropsychiatry pipeline

Ayisha Sharma

News Reporter

A UK biotech named after the Welsh word for dragon has emerged from stealth with a Phase 2-ready candidate for depression and an oversubscribed Series …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sanofi-backed Welsh biotech secures $140M for neuropsychiatry pipeline

Ayisha Sharma

News Reporter

Sign up to read this article for free.

FDA unveils one-year pilot to speed some new drugs to market in just one month

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

Dyne pivots on primary endpoint, delays filing for DM1 drug

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?

Sanofi-backed Welsh biotech se­cures $140M for neu­ropsy­chi­a­try pipeline

Ayisha Sharma

News Reporter

Sign up to read this article for free.

FDA un­veils one-year pi­lot to speed some new drugs to mar­ket in just one month

Af­ter a qui­et year, Xaira un­wraps some of its AI re­search, eye­ing a vir­tu­al cell

Lil­ly to bol­ster gene edit­ing pipeline, buy­ing Verve for up to $1.3B

Dyne piv­ots on pri­ma­ry end­point, de­lays fil­ing for DM1 drug

Or­phan drug, PBM changes are ex­clud­ed from Sen­ate ver­sion of Trump tax bill

This com­pa­ny has spent a decade in­no­vat­ing NGS-based com­pan­ion di­ag­nos­tics world­wide–what’s next?

Sanofi-backed Welsh biotech secures $140M for neuropsychiatry pipeline

FDA unveils one-year pilot to speed some new drugs to market in just one month

After a quiet year, Xaira unwraps some of its AI research, eyeing a virtual cell

Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B

Dyne pivots on primary endpoint, delays filing for DM1 drug

Orphan drug, PBM changes are excluded from Senate version of Trump tax bill

This company has spent a decade innovating NGS-based companion diagnostics worldwide–what’s next?